vimarsana.com
Home
Live Updates
Long-term risk of inflammatory bowel disease after endoscopi
Long-term risk of inflammatory bowel disease after endoscopi
Long-term risk of inflammatory bowel disease after endoscopic biopsy with normal mucosa: A population-based, sibling-controlled cohort study in Sweden
Jiangwei Sun and colleagues investigate the long-term risk of inflammatory bowel disease after endoscopic biopsy with normal mucosa in a Swedish cohort.
Related Keywords
China ,
Sweden ,
Montreal ,
Quebec ,
Canada ,
United States ,
Stockholm ,
North Carolina ,
Texas ,
Swedish ,
Chinese ,
Karolinska Institutet ,
Bristol Myer Squibb ,
Vifor Pharma ,
Falk Pharma ,
Sanjay Basu ,
Tillotts Pharma ,
Swedish National Board Of Health ,
International Classification Of Diseases ,
Swedish Longitudinal Integrated Database For Health Insurance ,
Novartis ,
National Patient Register ,
Pfizer ,
Swedish Ethical Review Authority ,
Beker Foundation ,
Chinese Scholarship Council ,
Blackwell ,
International Classification Of Disease ,
Prometheus Laboratories Inc ,
Harvard Medical School ,
Swedish Research Council ,
Falk Foundation ,
American College Of Gastroenterology Senior Research Award ,
Creative Commons Attribution License ,
Statistics Sweden ,
Swedish National Board ,
Swedish Ethical Review ,
Index Pharma ,
Thermo Fisher Scientific ,
American College ,
Gastroenterology Senior Research Award ,
Epidemiology Strengthened ,
Pathology Reports ,
International Classification ,
Systematized Nomenclature ,
Swedish Total Population Register ,
Swedish Multi Generation Register ,
Total Population Register ,
Swedish Longitudinal Integrated Database ,
Health Insurance ,
Labour Market Studies ,
Prescribed Drug Register ,
College Station ,
Observational Studies ,
Regional Ethics Review Board ,
Therapeutic Chemical ,
Inflammatory Bowel Disease ,
Biopsy ,
Epidemiology ,
Endoscopy ,
Medical Risk Factors ,
Cancer Risk Factors ,
Ulcerative Colitis ,